This search combines search strings from the content search (i.e. "Full Text", "Author", "Title", "Abstract", or "Keywords") with "Article Type" and "Publication Date Range" using the AND operator.
Beilstein J. Nanotechnol. 2022, 13, 1432–1444, doi:10.3762/bjnano.13.118
Scheme 1: Schematic diagram of the preparation of AB-LNPs.
Scheme 2: Synthesis of BDP. (a) 2,4-dimethylpyrrole, TFA, DCM, 25°C, 8 h; DDQ, DCM, 25 °C, 0.5 h; TEA, BF3·OEt...
Scheme 3: Preparation orders and appearance of different formed AB-LNPs. Method A: Au3+ was added to the pref...
Figure 1: The characterization of AB-LNPs. (a) Size distribution of Au-LNPs and AB-LNPs. Digital photo of AB-...
Figure 2: Photothermal properties of AB-LNPs. (a) Photothermal heating curves for AB-LNPs at different BDP co...
Figure 3: Stability and drug release properties of AB-LNPs. Changes of (a) particle size and (b) zeta potenti...
Figure 4: Cellular uptake of AB-LNPs. Cellular uptake efficiency of 4T1 cells treated with (a) AB-LNPs or (c)...
Figure 5: In vitro anti-proliferative activities of AB-LNPs with and without laser irradiation. (a) Cell viab...
Beilstein J. Nanotechnol. 2019, 10, 1933–1942, doi:10.3762/bjnano.10.189
Figure 1: (A) The structure of diosgenin. (B) The structure of FZU-0021-194-P2. (C) X-ray crystallographic an...
Figure 2: In vitro anticancer activity of diosgenin (Di) and its derivative FZU-0021-194-P2 (P2). (A) The ant...
Figure 3: Preparation and characterization of Di phytosomes (DiP) and P2 phytosomes (P2P). (A) Schematic illu...
Figure 4: In vitro antiproliferative activity of blank lipid nanoparticle (P), DiP, and P2P. (A) The cytotoxi...
Figure 5: (A) Cell cycle analysis of A549 and PC9 cells after treated with DiP and P2P for 72 h. (B) Cell apo...
Beilstein J. Nanotechnol. 2016, 7, 1861–1870, doi:10.3762/bjnano.7.178
Figure 1: Schematic illustration of the preparation procedure for MCNs. MIF-loaded CNs were prepared by a con...
Figure 2: The influence of the preparation conditions including Cs concentration (A), Cs/MIF mass ratio (B), ...
Figure 3: FITR spectra of (A) MIF, (B) blank CNs, and (C) MCNs. The MCNs formulation showed the characteristi...
Figure 4: XRD spectra of (A) Cs, (B) blank CNs, (C) MIF, and (D) MCNs. The XRD analysis of MCNs showed the de...
Figure 5: (A) DLS measurements of (1) CNs and (2) MCNs. (B) AFM images of (1) CNs and (2) MCNs.
Figure 6: In vitro release profiles of MIF from MCNs at pH 2.5 and 7.4. The release of MIF from the dialysis ...
Figure 7: In vitro cytotoxicity of CNs, MIF and MCNs against A549 (A), Hela (B), RL95-2 (C), and HepG2 cells ...
Figure 8: In vivo plasma concentration vs time of different MIF formulations. Male SD rats were given a singl...